復星醫藥(600196.SH):重組抗PD-1人源化單克隆抗體注射液聯合化療用於新輔助/輔助治療胃癌啟動III期臨牀研究
格隆匯12月12日丨復星醫藥(600196.SH)公佈,近日,公司控股子公司上海復宏漢霖生物技術股份有限公司(“復宏漢霖”)於中國境內(不包括港澳台地區,下同)就重組抗PD-1人源化單克隆抗體注射液(即HLX10;“該新藥”)聯合化療用於新輔助/輔助治療胃癌啟動III期臨牀研究。
該新藥為集團自主研發的創新型治療用生物製品,主要用於實體瘤治療,目前也正進一步探索慢性乙型肝炎治療的可能性。
截至公告日,於中國境內上市的重組抗PD-1人源化單克隆抗體注射液包括默沙東製藥有限公司的可瑞達®、美國百時美施貴寶公司的歐狄沃®等。根據IQVIA CHPA最新數據(由IQVIA提供,IQVIA是全球領先的醫藥健康產業專業信息和戰略諮詢服務提供商),2018年度,重組抗PD-1人源化單克隆抗體注射液於中國境內銷售額約為人民幣2668萬元。
截至2019年11月,集團現階段針對該新藥的累計研發投入為人民幣約30777萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.